Last checked at 11 Jun 2021 08:00
11 June 2021
IQ-AI Ltd
("IQ-AI" or the "Company")
IQAI Awarded "Gad-Free" Patent For Medical Imaging Procedures
IQ-AI Limited (LON: IQAI), and its subsidiary, Imaging Biometrics, LLC (IB) announced today that its synthetic T1+C ("Gad-Free") software application was awarded a patent by the U.S. Patent and Trademark Office. This ground-breaking technology eliminates the need to intravenously inject contrast agent during medical imaging procedures. The patent underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.
The fully automated AI platform accepts commonly acquired non-contrast medical images as inputs, and outputs a synthetic contrast enhanced image series that mimic actual, with contrast, images. The 0% contrast dose approach offers remarkable benefits which include a more comfortable patient experience, and the alleviation of potential problems arising from the long-term effects of repeated Gadolinium-based contrast agent (GBCA) use. While the long-term side effects of GBCAs remain unclear, a non-contrast alternative negates the safety implications for patients as well as potential liability concerns for healthcare providers.
"This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally," said Trevor Brown, CEO of IQAI.
The Directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited Trevor Brown/Vinod Kaushal/Qu Li Tel: 020 7469 0930 |
Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Mark Anwyl Tel: 020 7220 9797 |
ABOUT Imaging Biometrics, LLC
Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.